Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


21.01.2019

1 Ann Thorac Surg
1 Anticancer Res
1 Arch Bronconeumol
12 BMC Cancer
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Res
2 Cancer Sci
2 Clin Cancer Res
2 Clin Lung Cancer
3 Eur J Cancer
4 Eur Respir J
4 Int J Cancer
1 J Cancer Res Clin Oncol
2 J Thorac Cardiovasc Surg
2 J Thorac Oncol
30 Lung Cancer
2 N Engl J Med
5 PLoS One
1 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Thorac Surg

  1. GRANNIS FW JR
    The Importance of Smoking Cessation on Surgical Outcome in Primary Lung Cancer (Commentary).
    Ann Thorac Surg. 2019 Jan 11. pii: S0003-4975(19)30072.
    PubMed     Text format    


    Anticancer Res

  2. TAMIYA H, Mitani A, Saito A, Ishimori T, et al
    Exosomal MicroRNA Expression Profiling in Patients with Lung Adenocarcinoma-associated Malignant Pleural Effusion.
    Anticancer Res. 2018;38:6707-6714.
    PubMed     Text format     Abstract available


    Arch Bronconeumol

  3. MUINELO-ROMAY L, Garcia-Gonzalez J, Leon-Mateos L
    Lung Cancer and Liquid Biopsy: Realities and Challenges in Routine Clinical Practice.
    Arch Bronconeumol. 2019 Jan 10. pii: S0300-2896(18)30455.
    PubMed     Text format    


    BMC Cancer

  4. MARKOCZY Z, Sarosi V, Kudaba I, Galffy G, et al
    Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial.
    BMC Cancer. 2018;18:598.
    PubMed     Text format     Abstract available

  5. WEI X, Zhang K, Qin H, Zhu J, et al
    GMDS knockdown impairs cell proliferation and survival in human lung adenocarcinoma.
    BMC Cancer. 2018;18:600.
    PubMed     Text format     Abstract available

  6. ZHENG J, Jia L, Mori S, Kodama T, et al
    Evaluation of metastatic niches in distant organs after surgical removal of tumor-bearing lymph nodes.
    BMC Cancer. 2018;18:608.
    PubMed     Text format     Abstract available

  7. BORM KJ, Oechsner M, Wiegandt M, Hofmeister A, et al
    Moving targets in 4D-CTs versus MIP and AIP: comparison of patients data to phantom data.
    BMC Cancer. 2018;18:760.
    PubMed     Text format     Abstract available

  8. SAHIN IH, Elias H, Chou JF, Capanu M, et al
    Pancreatic adenocarcinoma: insights into patterns of recurrence and disease behavior.
    BMC Cancer. 2018;18:769.
    PubMed     Text format     Abstract available

  9. KIM IA, Lee JS, Kim HJ, Kim WS, et al
    Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study.
    BMC Cancer. 2018;18:768.
    PubMed     Text format     Abstract available

  10. HUANG H, Tong TT, Yau LF, Chen CY, et al
    LC-MS based sphingolipidomic study on A549 human lung adenocarcinoma cell line and its taxol-resistant strain.
    BMC Cancer. 2018;18:799.
    PubMed     Text format     Abstract available

  11. ISAKA T, Nakayama H, Ito H, Yokose T, et al
    Impact of the epidermal growth factor receptor mutation status on the prognosis of recurrent adenocarcinoma of the lung after curative surgery.
    BMC Cancer. 2018;18:959.
    PubMed     Text format     Abstract available

  12. ZHOU F, Ma W, Li W, Ni H, et al
    Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs.
    BMC Cancer. 2018;18:1033.
    PubMed     Text format     Abstract available

  13. ROMINE PE, Martins RG, Eaton KD, Wood DE, et al
    Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome.
    BMC Cancer. 2019;19:70.
    PubMed     Text format     Abstract available

  14. ZHOU W, Chen X, Hu Q, Chen X, et al
    Galectin-3 activates TLR4/NF-kappaB signaling to promote lung adenocarcinoma cell proliferation through activating lncRNA-NEAT1 expression.
    BMC Cancer. 2018;18:580.
    PubMed     Text format     Abstract available

  15. BUCZEK E, Denslow A, Mateuszuk L, Proniewski B, et al
    Alterations in NO- and PGI2- dependent function in aorta in the orthotopic murine model of metastatic 4T1 breast cancer: relationship with pulmonary endothelial dysfunction and systemic inflammation.
    BMC Cancer. 2018;18:582.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  16. LUSK CM, Wenzlaff AS, Watza D, Sieren JC, et al
    Quantitative imaging markers of lung function in a smoking population distinguish COPD sub-groups with differential lung cancer risk.
    Cancer Epidemiol Biomarkers Prev. 2019 Jan 14. pii: 1055-9965.EPI-18-0886.
    PubMed     Text format     Abstract available


    Cancer Res

  17. TIMANER M, Letko-Khait N, Kotsofruk R, Benguigui M, et al
    Therapy-educated mesenchymal stem cells enrich for tumor initiating cells.
    Cancer Res. 2018 Jan 4. pii: 0008-5472.CAN-17-1547.
    PubMed     Text format     Abstract available

  18. SILINA K, Soltermann A, Attar FM, Casanova R, et al
    Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
    Cancer Res. 2018;78:1308-1320.
    PubMed     Text format     Abstract available


    Cancer Sci

  19. UCHIDA A, Seki N, Mizuno K, Misono S, et al
    Involvement of dual-strand of the miR-144 duplex and their targets in the pathogenesis of lung squamous cell carcinoma.
    Cancer Sci. 2019;110:420-432.
    PubMed     Text format     Abstract available

  20. WAHIDUZZAMAN M, Karnan S, Ota A, Hanamura I, et al
    Establishment and characterization of CRISPR/Cas9-mediated NF2(-/-) human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma.
    Cancer Sci. 2019;110:180-193.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  21. MARTINEZ P, Peters S, Stammers T, Soria JC, et al
    Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer.
    Clin Cancer Res. 2019 Jan 14. pii: 1078-0432.CCR-18-3904.
    PubMed     Text format     Abstract available

  22. DE GOEJE PL, Poncin M, Bezemer K, Kaijen-Lambers MEH, et al
    Induction of peripheral effector CD8 T cell proliferation by combination of paclitaxel, carboplatin and bevacizumab in non-small cell lung cancer patients.
    Clin Cancer Res. 2019 Jan 14. pii: 1078-0432.CCR-18-2243.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  23. SCHWARZ M, Kocher F, Niedersuess-Beke D, Rudzki J, et al
    Immunosuppression for Immune Checkpoint-related Toxicity Can Cause Pneumocystis Jirovecii Pneumonia (PJP) in Non-small-cell Lung Cancer (NSCLC): A Report of 2 Cases.
    Clin Lung Cancer. 2018 Dec 19. pii: S1525-7304(18)30330.
    PubMed     Text format    

  24. JANSSENS A, Derijcke S, Galdermans D, Daenen M, et al
    Prognostic Understanding and Quality of Life in Patients With Advanced Lung Cancer: A Multicenter Study.
    Clin Lung Cancer. 2018 Dec 13. pii: S1525-7304(18)30307.
    PubMed     Text format     Abstract available


    Eur J Cancer

  25. PRADERE P, Boutros C, Scoazec JY, Dorfmuller P, et al
    Pulmonary nodules and immunotherapy: disease progression or toxicity of anti-PD1/anti-PDL1 checkpoint inhibitors?
    Eur J Cancer. 2018;93:144-146.
    PubMed     Text format    

  26. CHARRIER M, Mezquita L, Lueza B, Dupraz L, et al
    Circulating innate immune markers and outcomes in treatment-naive advanced non-small cell lung cancer patients.
    Eur J Cancer. 2019;108:88-96.
    PubMed     Text format     Abstract available

  27. TAKENAKA T, Kawai Y, Amano T
    Immune checkpoint therapy in proteinuric kidney disease.
    Eur J Cancer. 2018;95:120-122.
    PubMed     Text format    


    Eur Respir J

  28. SPENCER KL, Kennedy MPT, Lummis KL, Ellames DAB, et al
    Surgery or radiotherapy for stage I lung cancer? An intention to treat analysis.
    Eur Respir J. 2019 Jan 11. pii: 13993003.01568-2018.
    PubMed     Text format     Abstract available

  29. SHIN SH, Jeong DY, Lee KS, Cho JH, et al
    Which definition of central tumour is more predictive of occult mediastinal metastasis in non-small cell lung cancer patients with radiologic N0 disease?
    Eur Respir J. 2019 Jan 11. pii: 13993003.01508-2018.
    PubMed     Text format     Abstract available

  30. DECALUWE H, Dooms C, De Leyn P, Thomas P, et al
    Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease.
    Eur Respir J. 2018;51.
    PubMed     Text format    

  31. ADDEO A, Banna G
    Adding an invasive procedure will not necessarily change treatment or outcome of NSCLC patients with preoperative clinical N1 disease.
    Eur Respir J. 2018;51.
    PubMed     Text format    


    Int J Cancer

  32. CHEN K, Liu H, Liu Z, Luo S, et al
    Genetic Variants in RUNX3, AMD1 and MSRA in the Methionine Metabolic Pathway and Survival in Non-small Cell Lung Cancer Patients.
    Int J Cancer. 2019 Jan 16. doi: 10.1002/ijc.32128.
    PubMed     Text format     Abstract available

  33. MAEDA T, Hayashi T, Furukawa H, Iwasaki D, et al
    Immune-mediated antitumor effect of a transplanted lymph node.
    Int J Cancer. 2018;143:1224-1235.
    PubMed     Text format     Abstract available

  34. GARCIA-MONCLUS S, Lopez-Alemany R, Almacellas-Rabaiget O, Herrero-Martin D, et al
    EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma.
    Int J Cancer. 2018;143:1188-1201.
    PubMed     Text format     Abstract available

  35. XU H, Zhu X, Bao H, Wh Shek T, et al
    Genetic and clonal dissection of osteosarcoma progression and lung metastasis.
    Int J Cancer. 2018;143:1134-1142.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  36. PENG F, Li Q, Niu SQ, Shen GP, et al
    ZWINT is the next potential target for lung cancer therapy.
    J Cancer Res Clin Oncol. 2019 Jan 14. pii: 10.1007/s00432-018-2823.
    PubMed     Text format     Abstract available


    J Thorac Cardiovasc Surg

  37. FERNANDEZ FG, Kosinski AS, Tong BC, Furnary AP, et al
    Lack of correlation between short- and long-term performance after lung cancer surgery.
    J Thorac Cardiovasc Surg. 2018 Nov 27. pii: S0022-5223(18)33141.
    PubMed     Text format     Abstract available

  38. NELSON DB, Tayob N, Mitchell KG, Correa AM, et al
    Surgical margins and risk of local recurrence after wedge resection of colorectal pulmonary metastases.
    J Thorac Cardiovasc Surg. 2018 Nov 26. pii: S0022-5223(18)33149.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  39. QUINTANAL-VILLALONGA A, Molina-Pinelo S, Cirauqui C, Ojeda-Marquez L, et al
    FGFR1 cooperates with EGFR in lung cancer oncogenesis, and their combined inhibition shows improved efficacy.
    J Thorac Oncol. 2019 Jan 9. pii: S1556-0864(19)30008.
    PubMed     Text format     Abstract available

  40. DAVIES KD, Lomboy A, Lawrence CA, Yourshaw M, et al
    Brief Report: DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer.
    J Thorac Oncol. 2019 Jan 9. pii: S1556-0864(19)30007.
    PubMed     Text format     Abstract available


    Lung Cancer

  41. YU Y, Ou Q, Wu X, Bao H, et al
    Concomitant resistance mechanisms to multiple tyrosine kinase inhibitors in ALK-positive non-small cell lung cancer.
    Lung Cancer. 2019;127:19-24.
    PubMed     Text format     Abstract available

  42. THOMPSON JC, Fan R, Black T, Yu GH, et al
    Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients.
    Lung Cancer. 2019;127:25-33.
    PubMed     Text format     Abstract available

  43. CHOUAID C, Bensimon L, Clay E, Millier A, et al
    Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Lung Cancer. 2019;127:44-52.
    PubMed     Text format     Abstract available

  44. COUTINHO AD, Shah M, Lunacsek OE, Eaddy M, et al
    Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy.
    Lung Cancer. 2019;127:53-58.
    PubMed     Text format     Abstract available

  45. SAKAI H, Takeda M, Sakai K, Nakamura Y, et al
    Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non-small cell lung cancer negative for EGFR mutation and ALK fusion.
    Lung Cancer. 2019;127:59-65.
    PubMed     Text format     Abstract available

  46. DOTSON T, Bellinger C, Su J, Hansen K, et al
    Feasibility of lung cancer RNA acquisition from a single transbronchial or transthoracic needle pass (FASTT trial).
    Lung Cancer. 2019;127:6-11.
    PubMed     Text format     Abstract available

  47. HAQUE W, Verma V, Butler EB, Teh BS, et al
    Post-treatment mortality after definitive chemoradiotherapy versus trimodality therapy for locally advanced non-small cell lung cancer.
    Lung Cancer. 2019;127:76-83.
    PubMed     Text format     Abstract available

  48. GU X, Zhang Q, Chu YB, Zhao YY, et al
    Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
    Lung Cancer. 2019;127:84-89.
    PubMed     Text format     Abstract available

  49. YOON HS, Wen W, Long J, Zheng W, et al
    Association of oral health with lung cancer risk in a low-income population of African Americans and European Americans in the Southeastern United States.
    Lung Cancer. 2019;127:90-95.
    PubMed     Text format     Abstract available

  50. AULIAC JB, Perol M, Planchard D, Monnet I, et al
    Real-life efficacy of osimertinib in pretreated patients with advanced non-small cell lung cancer harboring EGFR T790M mutation.
    Lung Cancer. 2019;127:96-102.
    PubMed     Text format     Abstract available

  51. SCHUCHERT MJ, Normolle DP, Awais O, Pennathur A, et al
    Factors influencing recurrence following anatomic lung resection for clinical stage I non-small cell lung cancer.
    Lung Cancer. 2019;128:145-151.
    PubMed     Text format     Abstract available

  52. HASEGAWA H, Yasuda H, Hamamoto J, Masuzawa K, et al
    Efficacy of afatinib or osimertinib plus cetuximab combination therapy for non-small-cell lung cancer with EGFR exon 20 insertion mutations.
    Lung Cancer. 2019;127:146-152.
    PubMed     Text format     Abstract available

  53. MONSALVE AF, Hoag JR, Resio BJ, Chiu AS, et al
    Variable impact of prior cancer history on the survival of lung cancer patients.
    Lung Cancer. 2019;127:130-137.
    PubMed     Text format     Abstract available

  54. SHI JF, Wang L, Wu N, Li JL, et al
    Clinical characteristics and medical service utilization of lung cancer in China, 2005-2014: Overall design and results from a multicenter retrospective epidemiologic survey.
    Lung Cancer. 2019;128:91-100.
    PubMed     Text format     Abstract available

  55. MIZUGAKI H, Hamada A, Shibata T, Hosoda F, et al
    Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing.
    Lung Cancer. 2019;128:20-25.
    PubMed     Text format     Abstract available

  56. ZAMARRON E, Prats E, Tejero E, Pardo P, et al
    Static lung hyperinflation is an independent risk factor for lung cancer in patients with chronic obstructive pulmonary disease.
    Lung Cancer. 2019;128:40-46.
    PubMed     Text format     Abstract available

  57. HAMADA K, Irie M, Fujino Y, Hyodo M, et al
    Prognostic value of preoperative exercise capacity in patients undergoing thoracoscopic lobectomy for non-small cell lung cancer.
    Lung Cancer. 2019;128:47-52.
    PubMed     Text format     Abstract available

  58. NIEUWENHUIS L, van den Brandt PA
    Nut and peanut butter consumption and the risk of lung cancer and its subtypes: A prospective cohort study.
    Lung Cancer. 2019;128:57-66.
    PubMed     Text format     Abstract available

  59. YAN X, Wang H, Li P, Zhang G, et al
    Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Lung Cancer. 2019;128:6-12.
    PubMed     Text format     Abstract available

  60. BRONSERUD MM, Iachina M, Green A, Groenvold M, et al
    Patient-reported outcomes (PROs) in lung cancer: Experiences from a nationwide feasibility study.
    Lung Cancer. 2019;128:67-73.
    PubMed     Text format     Abstract available

  61. HORN L, Bauml J, Forde PM, Davis KL, et al
    Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer.
    Lung Cancer. 2019;128:74-90.
    PubMed     Text format     Abstract available

  62. CEDILLO JL, Bordas A, Arnalich F, Esteban-Rodriguez I, et al
    Anti-tumoral activity of the human-specific duplicated form of alpha7-nicotinic receptor subunit in tobacco-induced lung cancer progression.
    Lung Cancer. 2019;128:134-144.
    PubMed     Text format     Abstract available

  63. ABEL S, Hasan S, White R, Schumacher L, et al
    Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
    Lung Cancer. 2019;128:127-133.
    PubMed     Text format     Abstract available

  64. KOO HJ, Choi CM, Park S, Lee HN, et al
    Chest radiography surveillance for lung cancer: Results from a National Health Insurance database in South Korea.
    Lung Cancer. 2019;128:120-126.
    PubMed     Text format     Abstract available

  65. MURAWSKI M, Walter J, Schwarzkopf L
    Assessing the lung cancer comorbidome: An analysis of German claims data.
    Lung Cancer. 2019;127:122-129.
    PubMed     Text format     Abstract available

  66. PYO KH, Kim JH, Lee JM, Kim SE, et al
    Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models.
    Lung Cancer. 2019;127:112-121.
    PubMed     Text format     Abstract available

  67. WU YL, Zhao Q, Deng L, Zhang Y, et al
    Leptomeningeal metastasis after effective first-generation EGFR TKI treatment of advanced non-small cell lung cancer.
    Lung Cancer. 2019;127:1-5.
    PubMed     Text format     Abstract available

  68. STEVENS C, Smith SG, Quaife SL, Vrinten C, et al
    Interest in lifestyle advice at lung cancer screening: Determinants and preferences.
    Lung Cancer. 2019;128:1-5.
    PubMed     Text format     Abstract available

  69. GADGEEL SM, Lukas RV, Goldschmidt J, Conkling P, et al
    Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study.
    Lung Cancer. 2019;128:105-112.
    PubMed     Text format     Abstract available

  70. ITO K, Miura S, Sakaguchi T, Murotani K, et al
    The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Lung Cancer. 2019;128:113-119.
    PubMed     Text format     Abstract available


    N Engl J Med

  71. AMPOLLINI L, Rusca M
    Erythroderma and a Pulmonary Nodule.
    N Engl J Med. 2018;379:e41.
    PubMed     Text format    

  72. ANTONIA SJ, Villegas A, Daniel D, Vicente D, et al
    Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.
    N Engl J Med. 2018;379:2342-2350.
    PubMed     Text format     Abstract available


    PLoS One

  73. BALERMPAS P, Stera S, Muller von der Grun J, Loutfi-Krauss B, et al
    Repeated in-field radiosurgery for locally recurrent brain metastases: Feasibility, results and survival in a heavily treated patient cohort.
    PLoS One. 2018;13:e0198692.
    PubMed     Text format     Abstract available

  74. WONG ML, Shi Y, Fung KZ, Ngo S, et al
    Age, comorbidity, life expectancy, and pulmonary nodule follow-up in older veterans.
    PLoS One. 2018;13:e0200496.
    PubMed     Text format     Abstract available

  75. PETRELLI F, Lazzari C, Ardito R, Borgonovo K, et al
    Efficacy of ALK inhibitors on NSCLC brain metastases: A systematic review and pooled analysis of 21 studies.
    PLoS One. 2018;13:e0201425.
    PubMed     Text format     Abstract available

  76. YANG B, Jhun BW, Shin SH, Jeong BH, et al
    Comparison of four models predicting the malignancy of pulmonary nodules: A single-center study of Korean adults.
    PLoS One. 2018;13:e0201242.
    PubMed     Text format     Abstract available

  77. SUKIENNICKI GM, Marciniak W, Muszynska M, Baszuk P, et al
    Iron levels, genes involved in iron metabolism and antioxidative processes and lung cancer incidence.
    PLoS One. 2019;14:e0208610.
    PubMed     Text format     Abstract available


    Thorax

  78. EMERY JD, Murray SR, Walter FM, Martin A, et al
    The Chest Australia Trial: a randomised controlled trial of an intervention to increase consultation rates in smokers at risk of lung cancer.
    Thorax. 2019 Jan 10. pii: thoraxjnl-2018-212506.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: